$3.08
2.22% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US74587V1070
Symbol
PBYI
Sector
Industry

Puma Biotechnology, Inc. Stock price

$3.08
-0.15 4.64% 1M
-0.15 4.64% 6M
-1.25 28.87% YTD
-1.26 29.03% 1Y
-0.22 6.67% 3Y
-5.58 64.43% 5Y
-188.03 98.39% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.07 2.22%
ISIN
US74587V1070
Symbol
PBYI
Sector
Industry

Key metrics

Market capitalization $151.19m
Enterprise Value $140.83m
P/E (TTM) P/E ratio 6.49
EV/FCF (TTM) EV/FCF 4.18
EV/Sales (TTM) EV/Sales 0.58
P/S ratio (TTM) P/S ratio 0.62
P/B ratio (TTM) P/B ratio 2.13
Revenue growth (TTM) Revenue growth 6.30%
Revenue (TTM) Revenue $243.57m
EBIT (operating result TTM) EBIT $32.40m
Free Cash Flow (TTM) Free Cash Flow $33.68m
Cash position $96.73m
EPS (TTM) EPS $0.47
P/E forward 10.27
P/S forward 0.68
EV/Sales forward 0.63
Short interest 6.74%
Show more

Is Puma Biotechnology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Puma Biotechnology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Puma Biotechnology, Inc. forecast:

1x Buy
33%
1x Hold
33%
1x Sell
33%

Analyst Opinions

3 Analysts have issued a Puma Biotechnology, Inc. forecast:

Buy
33%
Hold
33%
Sell
33%

Financial data from Puma Biotechnology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
244 244
6% 6%
100%
- Direct Costs 75 75
36% 36%
31%
169 169
3% 3%
69%
- Selling and Administrative Expenses 72 72
13% 13%
30%
- Research and Development Expense 53 53
3% 3%
22%
44 44
12% 12%
18%
- Depreciation and Amortization 12 12
7% 7%
5%
EBIT (Operating Income) EBIT 32 32
14% 14%
13%
Net Profit 23 23
525% 525%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Puma Biotechnology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Puma Biotechnology, Inc. Stock News

Neutral
Business Wire
6 days ago
LOS ANGELES--(BUSINESS WIRE)--NCCN Guidelines for Cervical Cancer now include Puma's neratinib monotherapy for 2nd line or later use in patients with HER2-mutated tumors, Cat. 2A.
Positive
Seeking Alpha
13 days ago
Puma Biotechnology focuses on expanding neratinib sales and developing alisertib for breast and lung cancers, despite recent stock declines. Neratinib sales are stagnant, but the company remains stable financially. Alisertib shows early efficacy signals, with phase 2 trials ongoing, but its future success remains uncertain.
Neutral
Business Wire
24 days ago
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of an inducement award to a November new hire, as required under Nasdaq Listing Rule 5635(c)(4).
More Puma Biotechnology, Inc. News

Company Profile

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Head office United States
CEO Alan Auerbach
Employees 185
Founded 2010
Website www.pumabiotechnology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today